Discover 1,655 paid clinical trials in Raleigh, North Carolina. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,655
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
for
Colonic Neoplasms, Neoplasms, Colon
Location: Durham NC, Richmond VA, Bethesda MD, Detroit MI,
Sponsor: GlaxoSmithKline
Sex: All
Age: 18+
Code: NCT05855200
Phase 3, Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
for
Lung Diseases, Interstitial
Location: Durham NC, Gainesville FL, Philadelphia PA, New York NY,
Sponsor: GlaxoSmithKline
Sex: All
Age: 18+
Code: NCT06572384
Phase 3, Recruiting
A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)
for
Gastrointestinal Stromal Neoplasms
Location: Durham NC, Bethesda MD, Knoxville TN, Canton OH,
Sponsor: GlaxoSmithKline
Sex: All
Age: 18+
Code: NCT07585266
Phase 3, Recruiting
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
for
HIV Infections
Location: Durham NC, Greensboro NC, Wilmington NC, Charlotte NC,
Sponsor: ViiV Healthcare
Sex: All
Age: 18+
Code: NCT07202546
Phase 2, Recruiting
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
for
Gastrointestinal Neoplasms
Location: Durham NC, Charlotte NC, Richmond VA,
Sponsor: GlaxoSmithKline
Sex: All
Age: 18+
Code: NCT07218926
Phase 3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
for
Gastrointestinal Neoplasms
Location: Durham NC, New York NY, Toronto, Montreal, Madison WI,
Sponsor: GlaxoSmithKline
Sex: All
Age: 18+
Code: NCT06885034
Phase 1, Phase 2, Recruiting
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
for
Liver Diseases, Alcoholic
Location: Chapel Hill NC, Richmond VA, Detroit MI,
Sponsor: GlaxoSmithKline
Sex: All
Age: 18 - 70
Code: NCT06613698
Phase 2, Recruiting
Study of Levotofisopam 50 mg Three Times a Day (TID) Administered for 7 Days on Hyperuricemia and Gout
for
Hyperuricemia, Gout
Location: Durham NC
Sponsor: Pharmos
Sex: All
Age: 18 - 65
Code: NCT01519687
Phase 2, Recruiting
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
for
Sjögren's Syndrome
Location: Durham NC, Charlotte NC, Salisbury NC, Beckley WV,
Sponsor: Amgen
Sex: All
Age: 18+
Code: NCT06747949
Phase 3, Recruiting
ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors
for
Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors,
Location: Durham NC, Washington D.C. DC, Cincinnati OH,
Sponsor: Novartis Pharmaceuticals
Sex: All
Age: 1 - 70+
Code: NCT05868629
Recruiting
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
Location: Durham NC, Chapel Hill NC, Columbus OH, Chattanooga TN,
Sponsor: argenx
Sex: All
Age: 18+
Code: NCT07294170
Recruiting
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod